nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—DRD2—nicotine dependence	0.748	1	CbGaD
Zuclopenthixol—Thyroid disorder—Varenicline—nicotine dependence	0.0154	0.0951	CcSEcCtD
Zuclopenthixol—DRD5—Dopamine receptors—DRD2—nicotine dependence	0.00821	0.0984	CbGpPWpGaD
Zuclopenthixol—Withdrawal symptom—Varenicline—nicotine dependence	0.00615	0.038	CcSEcCtD
Zuclopenthixol—DRD1—Dopamine receptors—DRD2—nicotine dependence	0.00546	0.0654	CbGpPWpGaD
Zuclopenthixol—Drug withdrawal syndrome—Varenicline—nicotine dependence	0.00514	0.0318	CcSEcCtD
Zuclopenthixol—Extrapyramidal symptoms—Varenicline—nicotine dependence	0.00486	0.0301	CcSEcCtD
Zuclopenthixol—Libido increased—Varenicline—nicotine dependence	0.00415	0.0257	CcSEcCtD
Zuclopenthixol—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNA6—nicotine dependence	0.00382	0.0458	CbGpPWpGaD
Zuclopenthixol—Menstrual disorder—Varenicline—nicotine dependence	0.0037	0.0229	CcSEcCtD
Zuclopenthixol—Hyperlipidaemia—Varenicline—nicotine dependence	0.0035	0.0217	CcSEcCtD
Zuclopenthixol—Extrapyramidal disorder—Varenicline—nicotine dependence	0.00335	0.0207	CcSEcCtD
Zuclopenthixol—Mydriasis—Varenicline—nicotine dependence	0.00316	0.0196	CcSEcCtD
Zuclopenthixol—Rhinorrhoea—Varenicline—nicotine dependence	0.00311	0.0193	CcSEcCtD
Zuclopenthixol—Glycosuria—Varenicline—nicotine dependence	0.00311	0.0193	CcSEcCtD
Zuclopenthixol—Endocrine disorder—Varenicline—nicotine dependence	0.00304	0.0188	CcSEcCtD
Zuclopenthixol—Disturbance in attention—Varenicline—nicotine dependence	0.00291	0.018	CcSEcCtD
Zuclopenthixol—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0027	0.0324	CbGpPWpGaD
Zuclopenthixol—Abnormal dreams—Varenicline—nicotine dependence	0.00249	0.0154	CcSEcCtD
Zuclopenthixol—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNA5—nicotine dependence	0.00246	0.0295	CbGpPWpGaD
Zuclopenthixol—Salivary hypersecretion—Varenicline—nicotine dependence	0.00245	0.0152	CcSEcCtD
Zuclopenthixol—Nightmare—Varenicline—nicotine dependence	0.00244	0.0151	CcSEcCtD
Zuclopenthixol—Urine output increased—Varenicline—nicotine dependence	0.00228	0.0141	CcSEcCtD
Zuclopenthixol—Hypertonia—Varenicline—nicotine dependence	0.00221	0.0137	CcSEcCtD
Zuclopenthixol—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00211	0.0253	CbGpPWpGaD
Zuclopenthixol—Polyuria—Varenicline—nicotine dependence	0.00208	0.0129	CcSEcCtD
Zuclopenthixol—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNA3—nicotine dependence	0.00201	0.0241	CbGpPWpGaD
Zuclopenthixol—Libido decreased—Varenicline—nicotine dependence	0.00197	0.0122	CcSEcCtD
Zuclopenthixol—Hot flush—Varenicline—nicotine dependence	0.00196	0.0121	CcSEcCtD
Zuclopenthixol—Increased appetite—Varenicline—nicotine dependence	0.00195	0.0121	CcSEcCtD
Zuclopenthixol—Amnesia—Varenicline—nicotine dependence	0.00195	0.0121	CcSEcCtD
Zuclopenthixol—Menopausal symptoms—Varenicline—nicotine dependence	0.00194	0.012	CcSEcCtD
Zuclopenthixol—Thirst—Varenicline—nicotine dependence	0.00192	0.0119	CcSEcCtD
Zuclopenthixol—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00182	0.0112	CcSEcCtD
Zuclopenthixol—DRD5—Monoamine GPCRs—DRD2—nicotine dependence	0.00182	0.0218	CbGpPWpGaD
Zuclopenthixol—Migraine—Varenicline—nicotine dependence	0.0018	0.0112	CcSEcCtD
Zuclopenthixol—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNB2—nicotine dependence	0.00177	0.0212	CbGpPWpGaD
Zuclopenthixol—Urinary retention—Varenicline—nicotine dependence	0.00174	0.0108	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Varenicline—nicotine dependence	0.00169	0.0105	CcSEcCtD
Zuclopenthixol—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00168	0.0201	CbGpPWpGaD
Zuclopenthixol—Breast disorder—Varenicline—nicotine dependence	0.00165	0.0102	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Varenicline—nicotine dependence	0.00164	0.0101	CcSEcCtD
Zuclopenthixol—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNA4—nicotine dependence	0.00161	0.0192	CbGpPWpGaD
Zuclopenthixol—DRD5—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00153	0.0183	CbGpPWpGaD
Zuclopenthixol—Erectile dysfunction—Varenicline—nicotine dependence	0.00146	0.00902	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Varenicline—nicotine dependence	0.00144	0.00894	CcSEcCtD
Zuclopenthixol—Weight increased—Varenicline—nicotine dependence	0.00144	0.00891	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Varenicline—nicotine dependence	0.00143	0.00883	CcSEcCtD
Zuclopenthixol—HTR6—Monoamine GPCRs—DRD2—nicotine dependence	0.0014	0.0168	CbGpPWpGaD
Zuclopenthixol—Hepatobiliary disease—Varenicline—nicotine dependence	0.00133	0.00826	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Varenicline—nicotine dependence	0.00125	0.00774	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Varenicline—nicotine dependence	0.00125	0.00772	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Varenicline—nicotine dependence	0.00124	0.0077	CcSEcCtD
Zuclopenthixol—Urethral disorder—Varenicline—nicotine dependence	0.00124	0.00768	CcSEcCtD
Zuclopenthixol—DRD1—Hypothetical Network for Drug Addiction—DRD2—nicotine dependence	0.00124	0.0148	CbGpPWpGaD
Zuclopenthixol—Visual impairment—Varenicline—nicotine dependence	0.00122	0.00755	CcSEcCtD
Zuclopenthixol—DRD1—Monoamine GPCRs—DRD2—nicotine dependence	0.00121	0.0145	CbGpPWpGaD
Zuclopenthixol—Eye disorder—Varenicline—nicotine dependence	0.00118	0.00733	CcSEcCtD
Zuclopenthixol—Tinnitus—Varenicline—nicotine dependence	0.00118	0.00731	CcSEcCtD
Zuclopenthixol—HTR6—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00118	0.0141	CbGpPWpGaD
Zuclopenthixol—Cardiac disorder—Varenicline—nicotine dependence	0.00118	0.00728	CcSEcCtD
Zuclopenthixol—ADRA1A—G alpha (12/13) signalling events—FGD1—nicotine dependence	0.00117	0.014	CbGpPWpGaD
Zuclopenthixol—Angiopathy—Varenicline—nicotine dependence	0.00115	0.00711	CcSEcCtD
Zuclopenthixol—Immune system disorder—Varenicline—nicotine dependence	0.00114	0.00708	CcSEcCtD
Zuclopenthixol—Arrhythmia—Varenicline—nicotine dependence	0.00113	0.007	CcSEcCtD
Zuclopenthixol—Mental disorder—Varenicline—nicotine dependence	0.00111	0.00687	CcSEcCtD
Zuclopenthixol—Malnutrition—Varenicline—nicotine dependence	0.0011	0.00682	CcSEcCtD
Zuclopenthixol—Erythema—Varenicline—nicotine dependence	0.0011	0.00682	CcSEcCtD
Zuclopenthixol—Flatulence—Varenicline—nicotine dependence	0.00109	0.00672	CcSEcCtD
Zuclopenthixol—Vision blurred—Varenicline—nicotine dependence	0.00104	0.00643	CcSEcCtD
Zuclopenthixol—Tremor—Varenicline—nicotine dependence	0.00103	0.00639	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Varenicline—nicotine dependence	0.00102	0.00633	CcSEcCtD
Zuclopenthixol—DRD1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00101	0.0122	CbGpPWpGaD
Zuclopenthixol—Agitation—Varenicline—nicotine dependence	0.00101	0.00627	CcSEcCtD
Zuclopenthixol—Malaise—Varenicline—nicotine dependence	0.000994	0.00615	CcSEcCtD
Zuclopenthixol—Vertigo—Varenicline—nicotine dependence	0.00099	0.00613	CcSEcCtD
Zuclopenthixol—Syncope—Varenicline—nicotine dependence	0.000989	0.00612	CcSEcCtD
Zuclopenthixol—Palpitations—Varenicline—nicotine dependence	0.000974	0.00603	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Varenicline—nicotine dependence	0.000969	0.006	CcSEcCtD
Zuclopenthixol—Convulsion—Varenicline—nicotine dependence	0.000955	0.00591	CcSEcCtD
Zuclopenthixol—Hypertension—Varenicline—nicotine dependence	0.000952	0.00589	CcSEcCtD
Zuclopenthixol—Myalgia—Varenicline—nicotine dependence	0.000939	0.00581	CcSEcCtD
Zuclopenthixol—Anxiety—Varenicline—nicotine dependence	0.000935	0.00579	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.000932	0.00577	CcSEcCtD
Zuclopenthixol—Discomfort—Varenicline—nicotine dependence	0.000927	0.00574	CcSEcCtD
Zuclopenthixol—Dry mouth—Varenicline—nicotine dependence	0.000918	0.00568	CcSEcCtD
Zuclopenthixol—Flupentixol—DRD2—nicotine dependence	0.000897	0.126	CrCbGaD
Zuclopenthixol—HTR2A—Monoamine GPCRs—DRD2—nicotine dependence	0.000896	0.0107	CbGpPWpGaD
Zuclopenthixol—HRH1—Monoamine GPCRs—DRD2—nicotine dependence	0.000894	0.0107	CbGpPWpGaD
Zuclopenthixol—Shock—Varenicline—nicotine dependence	0.000885	0.00548	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Varenicline—nicotine dependence	0.000882	0.00546	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Varenicline—nicotine dependence	0.000881	0.00545	CcSEcCtD
Zuclopenthixol—Tachycardia—Varenicline—nicotine dependence	0.000878	0.00544	CcSEcCtD
Zuclopenthixol—ADRA1A—Monoamine GPCRs—DRD2—nicotine dependence	0.000877	0.0105	CbGpPWpGaD
Zuclopenthixol—Skin disorder—Varenicline—nicotine dependence	0.000874	0.00541	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Varenicline—nicotine dependence	0.00087	0.00538	CcSEcCtD
Zuclopenthixol—Anorexia—Varenicline—nicotine dependence	0.000858	0.00531	CcSEcCtD
Zuclopenthixol—Hypotension—Varenicline—nicotine dependence	0.000841	0.0052	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00082	0.00507	CcSEcCtD
Zuclopenthixol—ADRA2A—Monoamine GPCRs—DRD2—nicotine dependence	0.000815	0.00977	CbGpPWpGaD
Zuclopenthixol—Insomnia—Varenicline—nicotine dependence	0.000814	0.00504	CcSEcCtD
Zuclopenthixol—Dyspnoea—Varenicline—nicotine dependence	0.000802	0.00497	CcSEcCtD
Zuclopenthixol—Somnolence—Varenicline—nicotine dependence	0.0008	0.00495	CcSEcCtD
Zuclopenthixol—Acetophenazine—DRD2—nicotine dependence	0.000796	0.112	CrCbGaD
Zuclopenthixol—Dyspepsia—Varenicline—nicotine dependence	0.000792	0.0049	CcSEcCtD
Zuclopenthixol—Decreased appetite—Varenicline—nicotine dependence	0.000782	0.00484	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Varenicline—nicotine dependence	0.000777	0.00481	CcSEcCtD
Zuclopenthixol—Fatigue—Varenicline—nicotine dependence	0.000776	0.0048	CcSEcCtD
Zuclopenthixol—Pain—Varenicline—nicotine dependence	0.000769	0.00476	CcSEcCtD
Zuclopenthixol—Constipation—Varenicline—nicotine dependence	0.000769	0.00476	CcSEcCtD
Zuclopenthixol—HTR2A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000753	0.00903	CbGpPWpGaD
Zuclopenthixol—HRH1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000752	0.00901	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR ligand binding—TAS2R16—nicotine dependence	0.00075	0.00899	CbGpPWpGaD
Zuclopenthixol—Feeling abnormal—Varenicline—nicotine dependence	0.000741	0.00459	CcSEcCtD
Zuclopenthixol—ADRA1A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000737	0.00884	CbGpPWpGaD
Zuclopenthixol—Gastrointestinal pain—Varenicline—nicotine dependence	0.000736	0.00455	CcSEcCtD
Zuclopenthixol—Body temperature increased—Varenicline—nicotine dependence	0.000711	0.0044	CcSEcCtD
Zuclopenthixol—Abdominal pain—Varenicline—nicotine dependence	0.000711	0.0044	CcSEcCtD
Zuclopenthixol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000696	0.00834	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000687	0.00823	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000685	0.00821	CbGpPWpGaD
Zuclopenthixol—Hypersensitivity—Varenicline—nicotine dependence	0.000663	0.0041	CcSEcCtD
Zuclopenthixol—Asthenia—Varenicline—nicotine dependence	0.000646	0.004	CcSEcCtD
Zuclopenthixol—Pruritus—Varenicline—nicotine dependence	0.000637	0.00394	CcSEcCtD
Zuclopenthixol—DRD2—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000621	0.00745	CbGpPWpGaD
Zuclopenthixol—Diarrhoea—Varenicline—nicotine dependence	0.000616	0.00381	CcSEcCtD
Zuclopenthixol—Domperidone—DRD2—nicotine dependence	0.000603	0.0848	CrCbGaD
Zuclopenthixol—Dizziness—Varenicline—nicotine dependence	0.000595	0.00368	CcSEcCtD
Zuclopenthixol—HTR6—GPCR ligand binding—TAS2R16—nicotine dependence	0.000579	0.00694	CbGpPWpGaD
Zuclopenthixol—Vomiting—Varenicline—nicotine dependence	0.000572	0.00354	CcSEcCtD
Zuclopenthixol—Rash—Varenicline—nicotine dependence	0.000567	0.00351	CcSEcCtD
Zuclopenthixol—Dermatitis—Varenicline—nicotine dependence	0.000567	0.00351	CcSEcCtD
Zuclopenthixol—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000564	0.00676	CbGpPWpGaD
Zuclopenthixol—Headache—Varenicline—nicotine dependence	0.000564	0.00349	CcSEcCtD
Zuclopenthixol—ADRA2A—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000556	0.00667	CbGpPWpGaD
Zuclopenthixol—Nausea—Varenicline—nicotine dependence	0.000534	0.00331	CcSEcCtD
Zuclopenthixol—HTR2A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.000524	0.00628	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000498	0.00597	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000485	0.00581	CbGpPWpGaD
Zuclopenthixol—Thioproperazine—DRD2—nicotine dependence	0.000442	0.0621	CrCbGaD
Zuclopenthixol—Thiothixene—DRD2—nicotine dependence	0.000434	0.0611	CrCbGaD
Zuclopenthixol—Pipotiazine—DRD2—nicotine dependence	0.000434	0.0611	CrCbGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000424	0.00508	CbGpPWpGaD
Zuclopenthixol—DRD5—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000415	0.00498	CbGpPWpGaD
Zuclopenthixol—Prochlorperazine—DRD2—nicotine dependence	0.000415	0.0584	CrCbGaD
Zuclopenthixol—DRD5—Signaling by GPCR—TAS2R16—nicotine dependence	0.000385	0.00461	CbGpPWpGaD
Zuclopenthixol—DRD1—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000384	0.00461	CbGpPWpGaD
Zuclopenthixol—Amoxapine—DRD2—nicotine dependence	0.000382	0.0537	CrCbGaD
Zuclopenthixol—DRD2—GPCR ligand binding—TAS2R16—nicotine dependence	0.000376	0.00451	CbGpPWpGaD
Zuclopenthixol—Fluphenazine—DRD2—nicotine dependence	0.000375	0.0528	CrCbGaD
Zuclopenthixol—HTR6—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000374	0.00448	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00037	0.00444	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000369	0.00443	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR ligand binding—TAS2R16—nicotine dependence	0.000362	0.00434	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00035	0.0042	CbGpPWpGaD
Zuclopenthixol—HTR2A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00035	0.00419	CbGpPWpGaD
Zuclopenthixol—Chlorprothixene—DRD2—nicotine dependence	0.000342	0.0481	CrCbGaD
Zuclopenthixol—ADRA2A—GPCR ligand binding—TAS2R16—nicotine dependence	0.000337	0.00404	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—FGD1—nicotine dependence	0.000333	0.00399	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000327	0.00392	CbGpPWpGaD
Zuclopenthixol—Thioridazine—DRD2—nicotine dependence	0.000323	0.0455	CrCbGaD
Zuclopenthixol—DRD1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000322	0.00386	CbGpPWpGaD
Zuclopenthixol—HTR6—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00032	0.00384	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000318	0.00381	CbGpPWpGaD
Zuclopenthixol—HTR2A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000318	0.00381	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR ligand binding—OPRM1—nicotine dependence	0.000316	0.00379	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—FGD1—nicotine dependence	0.000302	0.00362	CbGpPWpGaD
Zuclopenthixol—DRD5—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.0003	0.0036	CbGpPWpGaD
Zuclopenthixol—Trifluoperazine—DRD2—nicotine dependence	0.0003	0.0422	CrCbGaD
Zuclopenthixol—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.0003	0.00359	CbGpPWpGaD
Zuclopenthixol—Loxapine—DRD2—nicotine dependence	0.000298	0.0419	CrCbGaD
Zuclopenthixol—HTR6—Signaling by GPCR—TAS2R16—nicotine dependence	0.000297	0.00356	CbGpPWpGaD
Zuclopenthixol—Perphenazine—DRD2—nicotine dependence	0.000297	0.0417	CrCbGaD
Zuclopenthixol—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000296	0.00354	CbGpPWpGaD
Zuclopenthixol—Quetiapine—DRD2—nicotine dependence	0.000291	0.0409	CrCbGaD
Zuclopenthixol—DRD2—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00029	0.00348	CbGpPWpGaD
Zuclopenthixol—DRD1—Circadian rythm related genes—DRD2—nicotine dependence	0.000284	0.00341	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000282	0.00337	CbGpPWpGaD
Zuclopenthixol—DRD1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000276	0.00331	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00027	0.00324	CbGpPWpGaD
Zuclopenthixol—DRD2—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000262	0.00314	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—FGD1—nicotine dependence	0.000257	0.00308	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000256	0.00306	CbGpPWpGaD
Zuclopenthixol—Clozapine—DRD2—nicotine dependence	0.00025	0.0352	CrCbGaD
Zuclopenthixol—HTR6—GPCR ligand binding—OPRM1—nicotine dependence	0.000244	0.00292	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000243	0.00291	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000239	0.00287	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000239	0.00286	CbGpPWpGaD
Zuclopenthixol—Chlorpromazine—DRD2—nicotine dependence	0.000235	0.0331	CrCbGaD
Zuclopenthixol—ADRA2A—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000234	0.00281	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000234	0.00281	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—FGD1—nicotine dependence	0.000233	0.00279	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000233	0.00279	CbGpPWpGaD
Zuclopenthixol—HTR6—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000232	0.00278	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR ligand binding—DRD2—nicotine dependence	0.000229	0.00274	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TAS2R16—nicotine dependence	0.000227	0.00272	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—FGD1—nicotine dependence	0.000221	0.00265	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000218	0.00261	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000213	0.00255	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR ligand binding—OPRM1—nicotine dependence	0.00021	0.00252	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000209	0.00251	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000209	0.0025	CbGpPWpGaD
Zuclopenthixol—DRD2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000208	0.0025	CbGpPWpGaD
Zuclopenthixol—HTR2A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000205	0.00246	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000205	0.00245	CbGpPWpGaD
Zuclopenthixol—HRH1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000204	0.00245	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—FGD1—nicotine dependence	0.000201	0.0024	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000201	0.0024	CbGpPWpGaD
Zuclopenthixol—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000199	0.00239	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—TAS2R16—nicotine dependence	0.000193	0.00231	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00019	0.00228	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—TAS2R16—nicotine dependence	0.00019	0.00228	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—TAS2R16—nicotine dependence	0.00019	0.00227	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000186	0.00223	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000186	0.00223	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—OPRM1—nicotine dependence	0.000179	0.00214	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—FGD1—nicotine dependence	0.000178	0.00214	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR ligand binding—DRD2—nicotine dependence	0.000176	0.00211	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TAS2R16—nicotine dependence	0.000175	0.0021	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000173	0.00207	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000173	0.00207	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000173	0.00207	CbGpPWpGaD
Zuclopenthixol—ADRA2A—G alpha (i) signalling events—DRD2—nicotine dependence	0.00017	0.00203	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000169	0.00203	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—FGD1—nicotine dependence	0.000167	0.002	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—FGD1—nicotine dependence	0.000164	0.00197	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—FGD1—nicotine dependence	0.000164	0.00196	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—OPRM1—nicotine dependence	0.000162	0.00194	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—FGD1—nicotine dependence	0.000161	0.00193	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR ligand binding—OPRM1—nicotine dependence	0.000159	0.0019	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKR1B10—nicotine dependence	0.000158	0.00189	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000157	0.00189	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR ligand binding—OPRM1—nicotine dependence	0.000156	0.00187	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR ligand binding—OPRM1—nicotine dependence	0.000156	0.00187	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR ligand binding—OPRM1—nicotine dependence	0.000153	0.00183	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR ligand binding—DRD2—nicotine dependence	0.000152	0.00182	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—FGD1—nicotine dependence	0.000151	0.00182	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TAS2R16—nicotine dependence	0.000151	0.00181	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—FGD1—nicotine dependence	0.000149	0.00179	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—FGD1—nicotine dependence	0.000149	0.00179	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—FGD1—nicotine dependence	0.000149	0.00178	CbGpPWpGaD
Zuclopenthixol—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000148	0.00178	CbGpPWpGaD
Zuclopenthixol—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000148	0.00177	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—FGD1—nicotine dependence	0.000146	0.00175	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000145	0.00174	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR ligand binding—OPRM1—nicotine dependence	0.000142	0.0017	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—OPRM1—nicotine dependence	0.000138	0.00165	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—FGD1—nicotine dependence	0.000138	0.00165	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—FGD1—nicotine dependence	0.000136	0.00163	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000135	0.00162	CbGpPWpGaD
Zuclopenthixol—DRD5—GPCR downstream signaling—DRD2—nicotine dependence	0.000129	0.00155	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—OPRM1—nicotine dependence	0.000125	0.0015	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKR1B10—nicotine dependence	0.000122	0.00146	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000119	0.00142	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—FGD1—nicotine dependence	0.000119	0.00142	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—DRD2—nicotine dependence	0.000117	0.00141	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TAS2R16—nicotine dependence	0.000114	0.00137	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR ligand binding—DRD2—nicotine dependence	0.000113	0.00135	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR ligand binding—DRD2—nicotine dependence	0.000113	0.00135	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TAS2R16—nicotine dependence	0.000112	0.00134	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TAS2R16—nicotine dependence	0.000112	0.00134	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—WASF2—nicotine dependence	0.000111	0.00133	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR ligand binding—DRD2—nicotine dependence	0.00011	0.00132	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TAS2R16—nicotine dependence	0.00011	0.00132	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—OPRM1—nicotine dependence	0.000108	0.00129	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—WASF1—nicotine dependence	0.000106	0.00128	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKR1B10—nicotine dependence	0.000105	0.00125	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR ligand binding—DRD2—nicotine dependence	0.000103	0.00123	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TAS2R16—nicotine dependence	0.000102	0.00122	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—DRD2—nicotine dependence	9.97e-05	0.00119	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—OPRM1—nicotine dependence	9.58e-05	0.00115	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—DRD2—nicotine dependence	9.05e-05	0.00109	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—OPRM1—nicotine dependence	8.96e-05	0.00107	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—FGD1—nicotine dependence	8.95e-05	0.00107	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—OPRM1—nicotine dependence	8.82e-05	0.00106	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—FGD1—nicotine dependence	8.8e-05	0.00106	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—OPRM1—nicotine dependence	8.8e-05	0.00105	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—FGD1—nicotine dependence	8.79e-05	0.00105	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—OPRM1—nicotine dependence	8.63e-05	0.00103	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—FGD1—nicotine dependence	8.62e-05	0.00103	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—DRD2—nicotine dependence	8.58e-05	0.00103	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—WASF2—nicotine dependence	8.57e-05	0.00103	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—WASF1—nicotine dependence	8.22e-05	0.000985	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—OPRM1—nicotine dependence	8.14e-05	0.000975	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—OPRM1—nicotine dependence	8.02e-05	0.000961	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—FGD1—nicotine dependence	8.01e-05	0.00096	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—OPRM1—nicotine dependence	8.01e-05	0.00096	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—OPRM1—nicotine dependence	7.99e-05	0.000958	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKR1B10—nicotine dependence	7.9e-05	0.000947	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CYP2A7—nicotine dependence	7.87e-05	0.000943	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—OPRM1—nicotine dependence	7.84e-05	0.00094	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—DRD2—nicotine dependence	7.79e-05	0.000934	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKR1B10—nicotine dependence	7.78e-05	0.000932	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKR1B10—nicotine dependence	7.76e-05	0.00093	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKR1B10—nicotine dependence	7.62e-05	0.000913	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—OPRM1—nicotine dependence	7.4e-05	0.000887	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—WASF2—nicotine dependence	7.38e-05	0.000884	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—OPRM1—nicotine dependence	7.28e-05	0.000873	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKR1B10—nicotine dependence	7.08e-05	0.000848	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—WASF1—nicotine dependence	7.07e-05	0.000848	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—DRD2—nicotine dependence	6.93e-05	0.00083	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—DRD2—nicotine dependence	6.37e-05	0.000764	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—OPRM1—nicotine dependence	6.37e-05	0.000763	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—DRD2—nicotine dependence	6.36e-05	0.000762	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—DRD2—nicotine dependence	6.24e-05	0.000748	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—DRD2—nicotine dependence	5.8e-05	0.000695	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—DRD2—nicotine dependence	5.79e-05	0.000694	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—DRD2—nicotine dependence	5.78e-05	0.000692	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—DRD2—nicotine dependence	5.67e-05	0.000679	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—WASF2—nicotine dependence	5.57e-05	0.000667	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—WASF2—nicotine dependence	5.48e-05	0.000657	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—WASF2—nicotine dependence	5.47e-05	0.000655	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—WASF2—nicotine dependence	5.37e-05	0.000643	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—DRD2—nicotine dependence	5.35e-05	0.000641	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—WASF1—nicotine dependence	5.34e-05	0.00064	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—DRD2—nicotine dependence	5.27e-05	0.000631	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—WASF1—nicotine dependence	5.25e-05	0.00063	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—WASF1—nicotine dependence	5.24e-05	0.000628	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—WASF1—nicotine dependence	5.14e-05	0.000617	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP2A7—nicotine dependence	5.13e-05	0.000614	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—WASF2—nicotine dependence	4.99e-05	0.000598	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—OPRM1—nicotine dependence	4.81e-05	0.000576	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—WASF1—nicotine dependence	4.78e-05	0.000573	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—OPRM1—nicotine dependence	4.73e-05	0.000567	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—OPRM1—nicotine dependence	4.72e-05	0.000566	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—OPRM1—nicotine dependence	4.63e-05	0.000555	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—DRD2—nicotine dependence	4.6e-05	0.000552	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—OPRM1—nicotine dependence	4.3e-05	0.000516	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—DRD2—nicotine dependence	3.42e-05	0.00041	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—DRD2—nicotine dependence	3.41e-05	0.000409	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—DRD2—nicotine dependence	3.35e-05	0.000401	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—DRD2—nicotine dependence	3.11e-05	0.000373	CbGpPWpGaD
